Literature DB >> 8836812

Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method.

M Tanaka1, K Hoshino, M Hohmura, H Ishida, A Kitamura, K Sato, I Hayakawa, T Nishino.   

Abstract

The effect of growth conditions on the antibacterial activity of DU-6859a against Staphylococcus auerus, Escherichia coli, and Pseudomonas aeruginosa was compared with those of levofloxacin, sparfloxacin, and ciprofloxacin. This activity was not affected by different media, inoculum size or the addition of human serum, but was decreased under acidic conditions, in human urine, and in the presence of magnesium and ferrous ion, as were the other quinolones tested. Time-kill curve studies demonstrated the bactericidal action of DU-6859a against S. aureus, Streptococcus pneumoniae, E. coli, and P. aeruginosa. Morphological alteration of these bacteria after exposure to DU-6859a also demonstrated its bactericidal activity. The frequency of spontaneous resistance to DU-6859a was less than or equal to those of the reference drugs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8836812     DOI: 10.1093/jac/37.6.1091

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases.

Authors:  T Akasaka; S Kurosaka; Y Uchida; M Tanaka; K Sato; I Hayakawa
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

2.  Bactericidal activity and postantibiotic effect of levofloxacin against anaerobes.

Authors:  S L Pendland; M Diaz-Linares; K W Garey; J G Woodward; S Ryu; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

3.  Improved antimicrobial activity of DU-6859a, a new fluoroquinolone, against quinolone-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates with alterations in GyrA and ParC proteins.

Authors:  T Deguchi; M Yasuda; M Nakano; S Ozeki; E Kanematsu; Y Nishino; Y Kawada
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

4.  Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV.

Authors:  T Akasaka; Y Onodera; M Tanaka; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

5.  In vitro and in vivo activities of sitafloxacin against Chlamydia spp.

Authors:  N Miyashita; Y Niki; T Matsushima
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.

Authors:  Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

7.  Modeling of transfer kinetics at the serum-cerebrospinal fluid barrier in rabbits with experimental meningitis: application to grepafloxacin.

Authors:  Marc Pfister; Liping Zhang; Margareta Hammarlund-Udenaes; Lewis B Sheiner; Cynthia M Gerber; Martin G Täuber; Philippe Cottagnoud
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 8.  Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections.

Authors:  R Nau; F Sörgel; H W Prange
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.